

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	January 29, 2024

Vivjoa™ (oteseconazole)

LENGTH OF AUTHORIZATION: 4 months

REVIEW CRITERIA:

- Patient must be diagnosed with recurrent vulvovaginal candidiasis.
- Medical records submitted confirming more than 3 episodes/year.
- Patient is not of reproductive potential (i.e. postmenopausal, permanent infertility).
- Documentation of failure of a maintenance course of oral fluconazole defined as 100mg, 150mg, or 200mg weekly for 6 months.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 150mg capsules.